Literature DB >> 25941617

STAT1-S727 - the license to kill.

Eva M Putz1, Dagmar Gotthardt1, Veronika Sexl1.   

Abstract

Serine phosphorylation has generally been considered indispensable for full transcriptional activity of STAT proteins. Recent data indicate that CDK8-mediated phosphorylation of signal transducer and activator of transcription 1 (STAT1) on S727 inhibits natural killer (NK) cell cytotoxicity and restrains tumor surveillance. These findings implicate CDK8 as a promising target for immunotherapy.

Entities:  

Keywords:  CDK, cyclin-dependent kinase; CDK8; CTLA-4, cytotoxic T lymphocyte antigen 4; FDA, food and drug administration; KLRG1, killer cell lectin-like receptor subfamily G member 1; MHC, major histocompatibility complex; NK cells; NK, natural killer; PD-1, programmed cell death 1; STAT1; STAT1, signal transducer and activator of transcription 1; immunotherapy; tumor immune surveillance

Year:  2014        PMID： 25941617      PMCID： PMC4292214          DOI： 10.4161/21624011.2014.955441

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  9 in total

1.  Breakthrough of the year 2013. Cancer immunotherapy.

Authors:  Jennifer Couzin-Frankel
Journal:  Science       Date:  2013-12-20       Impact factor: 47.728

2.  CDK8 maintains tumor dedifferentiation and embryonic stem cell pluripotency.

Authors:  Adam S Adler; Mark L McCleland; Tom Truong; Shari Lau; Zora Modrusan; Tim M Soukup; Merone Roose-Girma; Elizabeth M Blackwood; Ron Firestein
Journal:  Cancer Res       Date:  2012-02-16       Impact factor: 12.701

Review 3.  Natural killer cells preferentially target cancer stem cells; role of monocytes in protection against NK cell mediated lysis of cancer stem cells.

Authors:  Anahid Jewett; Han-Ching Tseng; Aida Arasteh; Saba Saadat; Russell E Christensen; Nicholas A Cacalano
Journal:  Curr Drug Deliv       Date:  2012-01       Impact factor: 2.565

4.  STAT1 acts as a tumor promoter for leukemia development.

Authors:  Boris Kovacic; Dagmar Stoiber; Richard Moriggl; Eva Weisz; René G Ott; Rita Kreibich; David E Levy; Hartmut Beug; Michael Freissmuth; Veronika Sexl
Journal:  Cancer Cell       Date:  2006-07       Impact factor: 31.743

5.  siRNA-mediated silencing of CDK8 inhibits proliferation and growth in breast cancer cells.

Authors:  Xiao-Yu Li; Qi-Feng Luo; Chuan-Kui Wei; Deng-Feng Li; Lin Fang
Journal:  Int J Clin Exp Pathol       Date:  2013-12-15

Review 6.  NK cell-based immunotherapy for malignant diseases.

Authors:  Min Cheng; Yongyan Chen; Weihua Xiao; Rui Sun; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2013-04-22       Impact factor: 11.530

7.  CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity.

Authors:  Ron Firestein; Adam J Bass; So Young Kim; Ian F Dunn; Serena J Silver; Isil Guney; Ellen Freed; Azra H Ligon; Natalie Vena; Shuji Ogino; Milan G Chheda; Pablo Tamayo; Stephen Finn; Yashaswi Shrestha; Jesse S Boehm; Supriya Jain; Emeric Bojarski; Craig Mermel; Jordi Barretina; Jennifer A Chan; Jose Baselga; Josep Tabernero; David E Root; Charles S Fuchs; Massimo Loda; Ramesh A Shivdasani; Matthew Meyerson; William C Hahn
Journal:  Nature       Date:  2008-09-14       Impact factor: 49.962

8.  The histone variant macroH2A suppresses melanoma progression through regulation of CDK8.

Authors:  Avnish Kapoor; Matthew S Goldberg; Lara K Cumberland; Kajan Ratnakumar; Miguel F Segura; Patrick O Emanuel; Silvia Menendez; Chiara Vardabasso; Gary Leroy; Claudia I Vidal; David Polsky; Iman Osman; Benjamin A Garcia; Eva Hernando; Emily Bernstein
Journal:  Nature       Date:  2010-12-23       Impact factor: 49.962

9.  CDK8-mediated STAT1-S727 phosphorylation restrains NK cell cytotoxicity and tumor surveillance.

Authors:  Eva Maria Putz; Dagmar Gotthardt; Gregor Hoermann; Agnes Csiszar; Silvia Wirth; Angelika Berger; Elisabeth Straka; Doris Rigler; Barbara Wallner; Amanda M Jamieson; Winfried F Pickl; Eva Maria Zebedin-Brandl; Mathias Müller; Thomas Decker; Veronika Sexl
Journal:  Cell Rep       Date:  2013-08-08       Impact factor: 9.423
  9 in total
  4 in total

1.  SNX8 mediates IFNγ-triggered noncanonical signaling pathway and host defense against Listeria monocytogenes.

Authors:  Jin Wei; Wei Guo; Huan Lian; Qing Yang; Heng Lin; Shu Li; Hong-Bing Shu
Journal:  Proc Natl Acad Sci U S A       Date:  2017-11-27       Impact factor: 11.205

Review 2.  Interplay between Janus Kinase/Signal Transducer and Activator of Transcription Signaling Activated by Type I Interferons and Viral Antagonism.

Authors:  Yuchen Nan; Chunyan Wu; Yan-Jin Zhang
Journal:  Front Immunol       Date:  2017-12-11       Impact factor: 7.561

Review 3.  Interferon Independent Non-Canonical STAT Activation and Virus Induced Inflammation.

Authors:  Yuchen Nan; Chunyan Wu; Yan-Jin Zhang
Journal:  Viruses       Date:  2018-04-14       Impact factor: 5.048

Review 4.  Interferon-γ: teammate or opponent in the tumour microenvironment?

Authors:  Angela M Gocher; Creg J Workman; Dario A A Vignali
Journal:  Nat Rev Immunol       Date:  2021-06-21       Impact factor: 53.106
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.